Skip to main content

Druggable Small Molecule Inhibitor of MEIS Proteins

Project description

Development of small molecule inhibitors of MEIS proteins

The MEIS1 (myeloid ecotropic viral insertion site 1) gene was identified at one of the viral integration sites in myeloid leukaemic cells and has been associated with oncogenic transformation. Its product, MEIS1 protein, acts as a co-factor of homeodomain-containing transcription factors that are involved in the control of numerous processes during embryonic development. Latest research has demonstrated that MEIS proteins are associated with decreased cardiac regeneration, decreased stem cell proliferation and cancer progression. The EU-funded MEISi project supports efforts of the biotech start-up Meinox to develop small drug inhibitors of MEIS protein as a potential critical factor in the treatment of myocardial injuries, bone failure and cancer. Currently, Meinox aims to conduct a feasibility study and risk analysis and to develop a robust commercialisation plan.

Field of science

  • /social sciences/economics and business/business and management/commerce
  • /medical and health sciences/medical biotechnology/cells technologies/stem cells
  • /natural sciences/biological sciences/cell biology/cell metabolism
  • /natural sciences/biological sciences/biochemistry/biomolecules/proteins

Call for proposal

H2020-SMEInst-2018-2020-1
See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

MEINOX ILAC TEKNOLOJILERI AS
Address
Resitpasa Mah. Katar Cad. Teknokent Ari 1 No: 2/5 Ickapi No: 19
34467 Sariyer Istanbul
Turkey
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000